No Detail Found!

Intracameral Bevacizumab Versus Subconjunctival Bevacizumab in the Treatment of Neovascular Glaucoma

Author(s)
Sharjeel Sultan Department of Ophthalmology, Dow University of Health Sciences, Civil Hospital, Karachi-Pakistan
Nisar A. Siyal Department of Ophthalmology, Dow University of Health Sciences, Civil Hospital,Karachi-Pakistan
Nazish Waris Baqai Institute of Diabetology and Endocrinology, Baqai Medical University, Karachi-Pakistan
A. Rasheed Khokar Department of Ophthalmology, Dow University of Health Sciences, Civil Hospital,Karachi-Pakistan
Abstract
Purpose: To compare the effect of intracameral Bevacizumab with sub-conjunctival Bevacizumab in the treatment of neovascular glaucoma. Study Design: Quasi Experimental study. Material and Methods: Patients with intractable Neo-vascular glaucoma visiting the outpatient department of civil hospital, Karachi were included in the study and followed up for 8 months. Patients with sulcus or scleral fixation IOLs and those who were treated with vitreoretinal surgeries were excluded. Patients were divided into two groups. Group A included patients treated with intracameral Bevacizumab and in group B, patients treated with sub-conjunctival Bevacizumab were included. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) and neovascularization of the iris (NVI) were compared between the two groups. Results: Thirty-eight eyes were included in the study; 24 (56.7%) right eyes and 14 (43.3%) left eyes. Most of the patients were males with mean age of 54.53 ± 7.2 years. Mean total injections per eye were 3.45 ± 1.73 in group A and 3.12 ± 2.10 in group B. Pre-injection BCVA (log MAR) was 0.48 ± 0.32 in group A and 0.34 ± 0.32 in group B. At 8 months, BCVA was 1.7 ± 0.2 in group A and 0.48 ± 0.34 in group B which was statistically significant. Pre-injection IOP (mm Hg) was 48.9 ± 1.8 in group A and 47.34 ± 1.8 in group B. Post-injection IOP was 28.7 ± 0.8 in group A (p = 0.001) and 34.2 ± 3.4 in group B (p = 0.11) at eight months. Conclusion: This study demonstrates that intracameral Bevacizumab significantly improves BCVA and controls IOP in neovascular glaucoma. However, sub-conjunctival Bevacizumab significantly improves BCVA but decrease in IOP is not statistically significant.
Publication Details
Page(s) 24-28
DOI DOI not available
Published Journal: Pakistan Journal of Ophthalmology , Volume: 36, Issue: 1, Year: 2020

Request the full text from PASTIC

Keywords
intracameral Bevacizumab
0

Citations

0

Downloads

57

Views